FDA submission

BMS Shows Breyanzi Benefit in Stem Cell Transplant-Ineligible LBCL

Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer

Allarity Therapeutics Submits NDA for Dovitinib for Treating Certain Renal Cancer Patients

AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer

Mirati Therapeutics Submits IND to FDA for PRMT5 Inhibitor in MTAP-Deleted Cancers

Novartis Seeking FDA, EMA Kymriah Approval for Follicular Lymphoma

Gilead Files for FDA Approval of Second-Line Yescarta for Large B-Cell Lymphoma

Tempus Submits PMA Application for Tumor Profiling Assay to FDA

FDA Accepts NDA for Aadi Bioscience's mTOR Inhibitor Fyarro in PEComa

FDA Accepts Allarity Therapeutics' PMA for Dovitinib Companion Test

Gilead's Yescarta Improves Large B-Cell Lymphoma Patients' Outcomes Over Standard Care in Zuma-7

Engineered TCR Therapy Demonstrates Durable Responses in Rare Sarcomas

Novartis On Track to Pursue Kymriah Approval in Follicular Lymphoma After Promising Results

Kiromic Biopharma Submits IND to FDA for CAR T-Cell Therapy Targeting Iso-Mesothelin

FDA Accepts Takeda's NDA for EGFR Exon20 Insertion-Mutated NSCLC Treatment

Gilead Submits Application With FDA to Expand Tecartus Use to Acute Lymphoblastic Lymphoma

Allarity Therapeutics Seeks FDA Premarket Approval for Prediction Tool as CDx for Dovitinib